Register entry
Corcept Therapeutics Incorporated
Data as of · How to read this entry
- Registered sites
- 0
- Active NDC listings
- 6
- Live patents
- 28
- Exclusivities
- 1
- Countries
- 0
Catalogue
Drug listings by form and route
66 active NDC listings: 6 human prescription drug. By marketing category: NDA 6.
| Dosage form | NDCs |
|---|---|
| kit | 4 |
| tablet | 2 |
| Route | NDCs |
|---|---|
| oral | 6 |
| Labeller name on the listing | NDCs |
|---|---|
| corcept therapeutics incorporated | 6 |
Exclusivity
Patents and exclusivities
28| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8921348 | KORLYMmifepristone | use | Aug 2028 |
| 10842801 | KORLYMmifepristone | use | Nov 2032 |
| 10500216 | KORLYMmifepristone | use | Mar 2033 |
| 10456392 | LIFYORLI (COPACKAGED)relacorilant | use | May 2033 |
| 11576907 | LIFYORLI (COPACKAGED)relacorilant | substance, product | May 2033 |
| 8859774 | LIFYORLI (COPACKAGED)relacorilant | substance, product | May 2033 |
| 9273047 | LIFYORLI (COPACKAGED)relacorilant | use | May 2033 |
| 10166242 | KORLYMmifepristone | use | Apr 2036 |
| 10166243 | KORLYMmifepristone | use | Apr 2036 |
| 10660904 | KORLYMmifepristone | use | Apr 2036 |
| 9943526 | KORLYMmifepristone | use | Apr 2036 |
| 10006924 | KORLYMmifepristone | use | Aug 2036 |
| 10495650 | KORLYMmifepristone | use | Aug 2036 |
| 9829495 | KORLYMmifepristone | use | Aug 2036 |
| 10151763 | KORLYMmifepristone | use | Jan 2037 |
| 10195214 | KORLYMmifepristone | use | Jun 2037 |
| 10842800 | KORLYMmifepristone | use | Jun 2037 |
| 11969435 | KORLYMmifepristone | use | Jun 2037 |
| 12097210 | KORLYMmifepristone | use | Jun 2037 |
| 10231983 | KORLYMmifepristone | use | Aug 2038 |
| 10314850 | KORLYMmifepristone | use | Aug 2038 |
| 10780097 | KORLYMmifepristone | use | Aug 2038 |
| 11925626 | LIFYORLI (COPACKAGED)relacorilant | product | Dec 2039 |
| 12514849 | LIFYORLI (COPACKAGED)relacorilant | product | Dec 2039 |
| 11464764 | LIFYORLI (COPACKAGED)relacorilant | product | Apr 2040 |
| 11285145 | LIFYORLI (COPACKAGED)relacorilant | use | May 2041 |
| 12589094 | LIFYORLI (COPACKAGED)relacorilant | use | May 2041 |
| 12152028 | LIFYORLI (COPACKAGED)relacorilant | product | Dec 2041 |
| Product | Exclusivity | Until |
|---|---|---|
| LIFYORLI (COPACKAGED)RELACORILANT | NCE New chemical entity | Mar 2031 |
Catalogue
Marketed products
6| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Korlym | Mifepristone | tablet, oral | 76346-073NDA |
| Lifyorli | Relacorilant | kit, oral | 76346-425NDA |
| Lifyorli | Relacorilant | kit, oral | 76346-450NDA |
| Lifyorli | Relacorilant | kit, oral | 76346-525NDA |
| Lifyorli | Relacorilant | kit, oral | 76346-550NDA |
| Mifepristone | Mifepristone | tablet, oral | 76346-654NDA |
Compare
Other companies listing relacorilant
- Catalent Pharma Solutions Inc.22 sites · 261 NDC
- Asymchem Laboratories (Tianjin) Co., Ltd.0 sites · 9 NDC
Enquiry
Common questions
- Is Corcept Therapeutics Incorporated FDA approved?
- Corcept Therapeutics Incorporated holds no registered establishment of its own; 6 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Corcept Therapeutics Incorporated make?
- 6 products are listed under Corcept Therapeutics Incorporated in the openFDA NDC Directory, most often as kit; tablet. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.